Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism

References

• RathbunSThe surgeon general’s call to action to prevent deep vein thrombosis and pulmonary embolismCirculation200911915e480e48219380627
   PubMed Web of Science ®Google Scholar
• Office of the Surgeon General (US), National Heart Lung, and Blood Institute (US)The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary EmbolismRockville (MD)Office of the Surgeon General (US)2008 Available from: http://www.ncbi.nlm.nih.gov/books/NBK44178/Accessed April 8, 2015
   Google Scholar
• HolbrookASchulmanSWittDMEvidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412_Supple152Se84S22315259
   PubMed Web of Science ®Google Scholar
• BauerKAPros and cons of new oral anticoagulantsHematology Am Soc Hematol Educ Program2013201346447024319220
   PubMed Web of Science ®Google Scholar
• YehCHGrossPLWeitzJIEvolving use of new oral anticoagulants for treatment of venous thromboembolismBlood201412471020102824923298
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• SchulmanSKakkarAKGoldhaberSZTreatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysisCirculation2014129776477224344086
   PubMed Web of Science ®Google Scholar
• BauersachsRBerkowitzSDBrennerBOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• BullerHRPrinsMHLensinAWOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• BullerHRDecoususHGrossoMAEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• ConnollySJEikelboomJDorianPBetrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)Eur Heart J201334201498150523487517
   PubMed Web of Science ®Google Scholar
• TurpieAGBauerKADavidsonBLA randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)Thromb Haemost20091011687619132191
   PubMed Web of Science ®Google Scholar
• CohenATHarringtonRGoldhaberSZThe design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) StudyAm Heart J2014167333534124576517
   PubMed Web of Science ®Google Scholar
• ZhangPHuangWWangLDiscovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl) benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitorBioorg Med Chem Lett20091982179218519297154
   PubMed Web of Science ®Google Scholar
• SinhaUEdwardsSTWongPWAntithrombotic activity of PRT54021, a potent oral direct factor Xa inhibitor, can be monitored using a novel prothrombinase inhibition bioassayBlood200610811272AA
   Web of Science ®Google Scholar
• AbeKSiuGEdwardsSAnimal models of thrombosis help predict the human therapeutic concentration of PRT54021, a potent oral factor Xa inhibitorBlood200610811270AA16527889
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govNCT01765868: A Human Phase I Absolute Bio-availability Study of PRT054021 in Healthy Male Volunteers 20122015 [cited July 31, 2013]. Available from: http://clinicaltrial.gov/ct2/show/NCT01765868?term=betrixaban&rank=5Accessed 8 April, 2015
   Google Scholar
• ClinicalTrials.govNCT01765855: An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects2015 Available from: http://clinicaltrial.gov/ct2/show/NCT01765855?term=betrixaban&rank=6Accessed April 8, 2015
   Google Scholar
• HutchaleelahaAYeCSongYLorenzTGretlerDLambingJLMetabolism and disposition of betrixaban and its lack of interaction with major CYP enzymesASH Annu Meet Abstr2012120212266
   Google Scholar
• BathalaMSMasumotoHOgumaTHeLLowrieCMendellJPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humansDrug Metab Dispos201240122250225522936313
   PubMed Web of Science ®Google Scholar
• BlechSEbnerTLudwig-SchwellingerEStangierJRothWThe metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humansDrug Metab Dispos200836238639918006647
   PubMed Web of Science ®Google Scholar
• WeinzCSchwarzTKubitzaDMueckWLangDMetabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humansDrug Metab Dispos20093751056106419196845
   PubMed Web of Science ®Google Scholar
• ZhangDHeKRaghavanNComparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humansDrug Metab Dispos20093781738174819420130
   PubMed Web of Science ®Google Scholar
• MorganrothJGretlerDDHollenbachSJLambingJLSinhaUAbsence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG studyExpert Opin Pharmacother201314151323216423
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govNCT01583218: Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)2015 Available from: http://clinicaltrial.gov/ct2/show/NCT01583218?term=betrixaban&rank=3Accessed April 8, 2015
   Google Scholar
• HullRDSchellongSMTapsonVFExtended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trialAnn Intern Med2010153181820621900
   PubMed Web of Science ®Google Scholar
• GoldhaberSZLeizoroviczAKakkarAKApixaban versus enoxaparin for thromboprophylaxis in medically ill patientsN Engl J Med2011365232167217722077144
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTEBullerHRRivaroxaban for thromboprophylaxis in acutely ill medical patientsN Engl J Med2013368651352323388003
   PubMed Web of Science ®Google Scholar
• CohenATHarringtonRGoldhaberSZRecognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAm Heart J2015169118618725497265
   PubMed Web of Science ®Google Scholar
• BarbarSNoventaFRossettoVA risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction scoreJ Thromb Haemost20108112450245720738765
   PubMed Web of Science ®Google Scholar
• SpyropoulosACAndersonFAJrFitzgeraldGPredictive and associative models to identify hospitalized medical patients at risk for VTEChest2011140370671421436241
   PubMed Web of Science ®Google Scholar
• WollerSCStevensSMJonesJPDerivation and validation of a simple model to identify venous thromboembolism risk in medical patientsAm J Med201112410947954e221962315
   PubMed Web of Science ®Google Scholar
• RosenbergDEichornAAlarconMMcCullaghLMcGinnTSpyropoulosACExternal validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health systemJ Am Heart Assoc201436e00115225404191
   PubMed Web of Science ®Google Scholar
• CohenATSpiroTESpyropoulosACD-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trialJ Thromb Haemost201412447948724460645
   PubMed Web of Science ®Google Scholar
• LuGDeGuzmanFRHollenbachSJA specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaNat Med20131944645123455714
   PubMed Web of Science ®Google Scholar
• CrowtherMAKittMMcClureMRandomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors (abstract)Arterioscler Thromb Vasc Biol201333A10
   Google Scholar
• CrowtherMAMathurVKittMA phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors (abstract)Blood2013122A3636
   Web of Science ®Google Scholar
• CrowtherMAKittMLorenzTA phase 2 randomized, double-blind, placebo-controlled trial of PRT4445, a novel, universal antidote for direct and indirect Factor Xa inhibitors (abstract)J Thromb Haemost201311AS20.1
   Web of Science ®Google Scholar
• CrowtherMLevyGLuGANNEXA™ A: a Phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by Andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors (abstract)Circulation201413021052126
   Google Scholar
• HollenbachSTanSDeGuzmanFPRT064445 reverses rivaroxaban induced antiacogulation in a rabbit liver laceration treatment model (abstract)Eur Heart J20133424
   Web of Science ®Google Scholar
• HollenbachSLuGDeGuzmanFAbstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model – only andexanet reverses markers of fXa-mediated anticoagulationCirculation2014130Suppl 2A14657
   Google Scholar